Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients.

Kobayashi M, Huang CL, Sonobe M, Kikuchi R, Ishikawa M, Kitamura J, Miyahara R, Menju T, Iwakiri S, Itoi K, Yasumizu R, Date H.

Exp Ther Med. 2012 Jun;3(6):952-958. Epub 2012 Mar 12.

2.

Intratumoral Wnt1 expression affects survivin gene expression in non-small cell lung cancer.

Nakashima N, Huang CL, Liu D, Ueno M, Yokomise H.

Int J Oncol. 2010 Sep;37(3):687-94.

PMID:
20664938
3.

Snail expression is associated with a poor prognosis in malignant pleural mesotheliomas.

Kobayashi M, Huang CL, Sonobe M, Kikuchi R, Ishikawa M, Imamura N, Kitamura J, Iwakiri S, Itoi K, Yasumizu R, Date H.

Ann Thorac Surg. 2013 Apr;95(4):1181-8. doi: 10.1016/j.athoracsur.2013.01.012. Epub 2013 Mar 1.

PMID:
23453740
4.

Wnt1 overexpression associated with tumor proliferation and a poor prognosis in non-small cell lung cancer patients.

Nakashima T, Liu D, Nakano J, Ishikawa S, Yokomise H, Ueno M, Kadota K, Huang CL.

Oncol Rep. 2008 Jan;19(1):203-9.

PMID:
18097596
5.

Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation.

Burt BM, Bader A, Winter D, Rodig SJ, Bueno R, Sugarbaker DJ.

Clin Cancer Res. 2012 Mar 15;18(6):1568-77. doi: 10.1158/1078-0432.CCR-11-1808. Epub 2012 Jan 18.

6.

Wnt3 gene expression promotes tumor progression in non-small cell lung cancer.

Nakashima N, Liu D, Huang CL, Ueno M, Zhang X, Yokomise H.

Lung Cancer. 2012 May;76(2):228-34. doi: 10.1016/j.lungcan.2011.10.007. Epub 2011 Nov 8.

PMID:
22070884
7.

Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor--an expression in non-small-cell lung cancer.

Huang CL, Liu D, Nakano J, Ishikawa S, Kontani K, Yokomise H, Ueno M.

J Clin Oncol. 2005 Dec 1;23(34):8765-73.

PMID:
16314637
8.

Comparison of SKIP expression in malignant pleural mesotheliomas with Ki-67 proliferation index and prognostic parameters.

Türkcü G, AlabalIk U, Keles AN, Ibiloglu I, Küçüköner M, Sen HS, Büyükbayram H.

Pol J Pathol. 2016 Jun;67(2):108-13.

9.

Overexpression of Numb suppresses tumor cell growth and enhances sensitivity to cisplatin in epithelioid malignant pleural mesothelioma.

Kang Y, Ding M, Tian G, Guo H, Wan Y, Yao Z, Li B, Lin D.

Oncol Rep. 2013 Jul;30(1):313-9. doi: 10.3892/or.2013.2429. Epub 2013 Apr 26.

PMID:
23624653
10.

Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.

Ohta Y, Shridhar V, Kalemkerian GP, Bright RK, Watanabe Y, Pass HI.

Cancer. 1999 Jun 15;85(12):2570-6.

PMID:
10375104
11.

CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection.

Yamada N, Oizumi S, Kikuchi E, Shinagawa N, Konishi-Sakakibara J, Ishimine A, Aoe K, Gemba K, Kishimoto T, Torigoe T, Nishimura M.

Cancer Immunol Immunother. 2010 Oct;59(10):1543-9. doi: 10.1007/s00262-010-0881-6. Epub 2010 Jun 22.

PMID:
20567822
12.

Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma.

Tsao AS, Harun N, Fujimoto J, Devito V, Lee JJ, Kuhn E, Mehran R, Rice D, Moran C, Hong WK, Shen L, Suraokar M, Wistuba I.

Ann Diagn Pathol. 2014 Jun;18(3):140-5. doi: 10.1016/j.anndiagpath.2014.02.005. Epub 2014 Feb 20.

13.

Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer.

Liu D, Nakano J, Ishikawa S, Yokomise H, Ueno M, Kadota K, Urushihara M, Huang CL.

Lung Cancer. 2007 Dec;58(3):384-91. Epub 2007 Aug 28.

PMID:
17728005
14.

Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma.

Burt BM, Rodig SJ, Tilleman TR, Elbardissi AW, Bueno R, Sugarbaker DJ.

Cancer. 2011 Nov 15;117(22):5234-44. doi: 10.1002/cncr.26143. Epub 2011 Apr 26.

15.

Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM).

Yoneda K, Tanaka F, Kondo N, Orui H, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Tsubota N, Sato A, Tsujimura T, Kuribayashi K, Fukuoka K, Nakano T, Hasegawa S.

Ann Surg Oncol. 2012 Dec;19(13):4229-37. doi: 10.1245/s10434-012-2506-0. Epub 2012 Jul 24.

PMID:
22825770
16.

Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.

Righi L, Papotti MG, Ceppi P, Billè A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G.

J Clin Oncol. 2010 Mar 20;28(9):1534-9. doi: 10.1200/JCO.2009.25.9275. Epub 2010 Feb 22.

PMID:
20177021
17.

Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.

Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozsas A, Kenessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, Brcic L, Kern I, Rozman A, Popper H, Zöchbauer-Müller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B.

J Pathol. 2015 Oct;237(2):203-14. doi: 10.1002/path.4567. Epub 2015 Jul 14.

PMID:
26011651
18.

Specific expression of human intelectin-1 in malignant pleural mesothelioma and gastrointestinal goblet cells.

Washimi K, Yokose T, Yamashita M, Kageyama T, Suzuki K, Yoshihara M, Miyagi Y, Hayashi H, Tsuji S.

PLoS One. 2012;7(7):e39889. doi: 10.1371/journal.pone.0039889. Epub 2012 Jul 2.

19.

Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma.

Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M, Erdas R, Cabras A, Kusamura S, Baratti D, Deraco M, Daidone MG.

Cell Oncol. 2007;29(6):453-66.

20.

Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.

Riquelme E, Suraokar MB, Rodriguez J, Mino B, Lin HY, Rice DC, Tsao A, Wistuba II.

J Thorac Oncol. 2014 Jul;9(7):998-1007. doi: 10.1097/JTO.0000000000000202.

Supplemental Content

Support Center